Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis

Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis

To evaluate efficacy and safety of lapatinib or trastuzumab alone or both plus chemotherapy for the treatment of breast cancer patients with positive HER-2 expression. Cochrane Central Register of Controlled Trials, PubMed, MEDLINE, OVID, Embase, Chinese Biomedical Literature Database, and China Aca...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:OncoTargets and therapy 2019-01, Vol.12, p.379-390
Hauptverfasser: Ma, Wenhua, Zhao, Fugang, Zhou, Changpeng, Zhang, Yongqian, Zhao, Yingchun, Li, Na, Xie, Peng
Format: Artikel
Sprache:eng
Schlagworte:
Adjuvant treatment
Bias
Breast cancer
Cancer
Cancer patients
Cancer therapies
Care and treatment
Chemotherapy
Comparative analysis
Diarrhea
Evidence-based medicine
Hospitals
Immunotherapy
Keywords
Medical research
Meta-analysis
Monoclonal antibodies
Online databases
Original Research
Pertuzumab
Quality
Skin diseases
Software
Statistical analysis
Studies
Systematic review
Targeted cancer therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To evaluate efficacy and safety of lapatinib or trastuzumab alone or both plus chemotherapy for the treatment of breast cancer patients with positive HER-2 expression. Cochrane Central Register of Controlled Trials, PubMed, MEDLINE, OVID, Embase, Chinese Biomedical Literature Database, and China Academic Journals Database were searched from 1994 through December 2017 using the keywords "breast cancer", "preoperative", "neo-adjuvant", "lapatinib", "pertuzumab", "Herceptin", and "trastuzumab". Meta-analysis found that pathological complete response (PCR; risk ratio [RR]=0.82, 95% CI: 0.72-0.93) and tall PCR (tPCR; RR=0.77, 95% CI: 0.67-0.88) of chemotherapy plus lapatinib were significantly less effective or safe compared to that of chemotherapy plus trastuzumab (
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S183304